ReviewExperimental and therapeutic medicine2019
Pemphigus vulgaris - approach and management.
Review in Experimental and therapeutic medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed.
- Recognizing Pemphigus Vulgaris in a Low Prevalence Setting: A Journey Through Multiple Diagnoses.Case reports in dermatological medicine · 2026Article
- The association between aromatic amino acids consumption and the severity of pemphigus vulgaris: a cross-sectional study.Scientific reports · 2025Article
- Juvenile pemphigus vulgaris: A narrative review.Medicine · 2025Review
- Article
- Navigating Treatment Dilemmas: Recalcitrant Pemphigus and the Burden of Multiple Comorbidities.Cureus · 2024Article
- Towards multiomic analysis of oral mucosal pathologies.Seminars in immunopathology · 2023Review
- Pain management of pemphigus vulgaris.BMJ case reports · 2022Article
- Pemphigus vulgaris in an elderly woman diagnosed with subacute thyroiditis: A case report.Aging medicine (Milton (N.S.W)) · 2022Article
- [Pemphigus vulgaris with exclusive affectation in the esophagus: a case report].Revista medica del Instituto Mexicano del Seguro Social · 2022Article
- Vesiculobullous Diseases.Medicina (Kaunas, Lithuania) · 2022Article
- Desmogleins 1, 3, and E-cadherin immunohistochemical expression within mucocutaneous pemphigus vulgaris.The Pan African medical journal · 2022Article
- An Updated Review of Pemphigus Diseases.Medicina (Kaunas, Lithuania) · 2021Review
- Simultaneous Oral and Umbilical Locations as a First Sign of Pemphigus Vulgaris.Case reports in dentistry · 2021Article
- Highlights of the 3rd conference of the Romanian Association of Immuno-Dermatology and the 37th conference of the Romanian Society of Immunology held in Bucharest between September 19 and 22, 2019.Experimental and therapeutic medicine · 2019Article
- ERK/MEK Pathway Regulates Th17 Cell Differentiation in Patients with Pemphigus Vulgaris.Indian journal of dermatologyArticle
- Current Therapeutic Modalities of Immunobullous Lesions.Contemporary clinical dentistryArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The place of pemphigus vulgaris (PV) among autoimmune bullous dermatoses is well known. In pemphigus, IgG autoantibodies are directed against desmogleins 1 and 3, which are part of the cadherin family of cell-cell adhesion molecules. These structures are responsible for maintaining the intercellular adherence in stratified squamous epithelia, such as the skin and oral mucosa. The incidence of autoimmune bullous dermatoses is steadily increasing, being associated with a high degree of morbidity. The pathophysiology of these dermatoses is very well understood, complemented by recent genetic studies. The gold standard for the diagnosis of pemphigus vulgaris is the detection of autoantibodies or complement component 3 by direct immunofluorescence microscopy of a perilesional biopsy. Early diagnosis and initiation of treatment are necessary in order to achieve a favorable prognosis. Although the first line of treatment is corticotherapy, there are no clear guidelines on dosing regimens, and long-term adverse effects are important. Corticosteroid-sparing adjuvant therapies have been employed in the treatment of PV, aiming to reduce the necessary cumulative dose of corticosteroids. In addition, therapies with anti-CD20 antibodies are used, but antigen-specific immune suppression-based treatments represent the future.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.